vs
ACRES Commercial Realty Corp.（ACR）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是ACRES Commercial Realty Corp.的1.8倍（$35.5M vs $20.0M），ACRES Commercial Realty Corp.净利率更高（31.6% vs -304.2%，领先335.9%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -6.5%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 3.3%）
皮拉马尔地产是一家印度房地产企业，2012年成立，总部位于印度孟买，隶属于皮拉马尔集团。公司专注于住宅及商业地产开发，目前在手开发项目总规模约达1500万平方英尺，知名项目包括Piramal Aranya、Piramal Mahalaxmi等。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ACR vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.0M | $35.5M |
| 净利润 | $6.3M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 30.8% | -304.8% |
| 净利率 | 31.6% | -304.2% |
| 营收同比 | -6.5% | 681.7% |
| 净利润同比 | -32.0% | 39.6% |
| 每股收益（稀释后） | $-0.41 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $20.0M | $35.5M | ||
| Q3 25 | $21.0M | $5.2M | ||
| Q2 25 | $21.9M | $19.2M | ||
| Q1 25 | $17.0M | $14.7M | ||
| Q4 24 | $21.4M | $4.5M | ||
| Q3 24 | $22.4M | $26.1M | ||
| Q2 24 | $20.9M | $14.4M | ||
| Q1 24 | $18.8M | $13.8M |
| Q4 25 | $6.3M | $-108.1M | ||
| Q3 25 | $18.0M | $-162.3M | ||
| Q2 25 | $4.3M | $-171.9M | ||
| Q1 25 | $-730.0K | $-202.5M | ||
| Q4 24 | $9.3M | $-178.9M | ||
| Q3 24 | $8.1M | $-95.8M | ||
| Q2 24 | $6.4M | $-97.5M | ||
| Q1 24 | $4.9M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 30.8% | -304.8% | ||
| Q3 25 | 85.8% | -3327.6% | ||
| Q2 25 | 19.8% | -916.8% | ||
| Q1 25 | -3.8% | -1297.9% | ||
| Q4 24 | 43.4% | -4042.4% | ||
| Q3 24 | 36.4% | -377.1% | ||
| Q2 24 | 30.8% | -697.4% | ||
| Q1 24 | 26.2% | -698.4% |
| Q4 25 | 31.6% | -304.2% | ||
| Q3 25 | 85.8% | -3135.3% | ||
| Q2 25 | 19.8% | -894.2% | ||
| Q1 25 | -4.3% | -1373.3% | ||
| Q4 24 | 43.5% | -3935.5% | ||
| Q3 24 | 36.0% | -367.5% | ||
| Q2 24 | 30.6% | -676.6% | ||
| Q1 24 | 26.2% | -662.4% |
| Q4 25 | $-0.41 | $-0.17 | ||
| Q3 25 | $1.34 | $-0.36 | ||
| Q2 25 | $-0.10 | $-0.41 | ||
| Q1 25 | $-0.80 | $-0.50 | ||
| Q4 24 | $0.51 | $-0.56 | ||
| Q3 24 | $0.36 | $-0.34 | ||
| Q2 24 | $0.21 | $-0.40 | ||
| Q1 24 | $0.07 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.8M | $743.3M |
| 总债务越低越好 | $1.6B | $9.6M |
| 股东权益账面价值 | $420.8M | $1.1B |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 3.68× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $83.8M | $743.3M | ||
| Q3 25 | $40.9M | $659.8M | ||
| Q2 25 | $42.7M | $525.1M | ||
| Q1 25 | $66.0M | $500.5M | ||
| Q4 24 | $56.7M | $594.4M | ||
| Q3 24 | $70.1M | $427.6M | ||
| Q2 24 | $89.6M | $474.3M | ||
| Q1 24 | $84.6M | $296.3M |
| Q4 25 | $1.6B | $9.6M | ||
| Q3 25 | $1.2B | $11.9M | ||
| Q2 25 | $1.3B | $14.2M | ||
| Q1 25 | $1.3B | $16.4M | ||
| Q4 24 | $1.4B | $19.0M | ||
| Q3 24 | $1.5B | $20.5M | ||
| Q2 24 | $1.6B | $22.9M | ||
| Q1 24 | $1.6B | — |
| Q4 25 | $420.8M | $1.1B | ||
| Q3 25 | $432.9M | $1.0B | ||
| Q2 25 | $425.3M | $919.1M | ||
| Q1 25 | $430.1M | $933.9M | ||
| Q4 24 | $439.1M | $1.0B | ||
| Q3 24 | $436.3M | $524.6M | ||
| Q2 24 | $434.0M | $584.4M | ||
| Q1 24 | $432.8M | $401.2M |
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.9B | $1.4B | ||
| Q3 24 | $2.0B | $726.5M | ||
| Q2 24 | $2.1B | $775.9M | ||
| Q1 24 | $2.1B | $557.8M |
| Q4 25 | 3.68× | 0.01× | ||
| Q3 25 | 2.76× | 0.01× | ||
| Q2 25 | 3.10× | 0.02× | ||
| Q1 25 | 2.97× | 0.02× | ||
| Q4 24 | 3.12× | 0.02× | ||
| Q3 24 | 3.43× | 0.04× | ||
| Q2 24 | 3.67× | 0.04× | ||
| Q1 24 | 3.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 0.65× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $4.1M | $-46.1M | ||
| Q3 25 | $-9.4M | $-117.4M | ||
| Q2 25 | $11.8M | $-76.4M | ||
| Q1 25 | $-4.6M | $-132.0M | ||
| Q4 24 | $19.4M | $-115.4M | ||
| Q3 24 | $8.4M | $-59.2M | ||
| Q2 24 | $6.9M | $-82.2M | ||
| Q1 24 | $3.3M | $-102.3M |
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
| Q4 25 | 0.65× | — | ||
| Q3 25 | -0.52× | — | ||
| Q2 25 | 2.72× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 1.05× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 0.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACR
| Other | $10.8M | 54% |
| Pacmulti JVLLC | $5.2M | 26% |
| Mccallum Jv Llc | $2.5M | 12% |
| Office Complex | $1.5M | 7% |
RXRX
暂无分部数据
